CureVax and Novavax Rally as CDC Reports Rising U.S. COVID-19, RSV, and Influenza Cases
Monday, Jan 6, 2025 4:05 pm ET
1min read The Centers for Disease Control and Prevention (CDC) has reported a surge in COVID-19, RSV, and influenza cases across the United States, leading to a rally in the shares of vaccine developers CureVax and Novavax. As the demand for vaccines increases, investors are showing renewed interest in these companies, driving up their stock prices.
Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.